Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant

Inclusion Criteria: * First or second (single or double) deceased or living donor kidney transplant received at least six months previously; * Immunosuppressive therapy with cyclosporin and mycophenolate mofetil (MMF); * Receiving an MMF dose of \<2/g/day because of any adverse event and/or altered laboratory test result attributed to MMF Exclusion Criteria: * • Subjects expected to discontinue cyclosporin therapy; * Patients with thrombocytopenia (\<75,000/mm3), an absolute neutrophil count of \<1,500/mm3 and/or leukopenia (\<2,500/mm3), or anemia (hemoglobin \<6 g/dl) at baseline; * Patients experiencing an acute rejection in the previous two months, with inadequate (creatininemia \>2.5 mg/dL) or worsening renal function in the previous two months.